We Develop
Life Changing Medicines

for Patients Living With Autoimmune Diseases

Our mission is to bring life-changing therapeutic benefits to patients living with autoimmune diseases.

A new era of CAR T-cell therapy

Kyverna is pioneering CAR T-cell therapies for autoimmune disease patients by harnessing the power of T cells to achieve a potentially sustained treatment-free remission by resetting the immune system.

Bringing the transformational experience of cell therapies to autoimmune diseases

We believe the success of CAR T-cell therapies in B cell-driven hematological malignancies can be leveraged to deliver therapeutic benefits in patients living with autoimmune diseases.

A patient-centric approach

We are a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.

How does CAR T-cell therapy work?

Cell therapy holds the potential to reset the immune system after a single infusion, aimed at achieving long-lasting, treatment-free remission.

01: Patient’s blood is collected and white blood cells (including T cells) are separated.

02: T cells are altered so that they can recognize, attack, and destroy the B cells.

03: Altered T cells are returned back to the patient via an intravenous infusion.

04: The CAR T cells attack B cells, including unhealthy B cells with the goal of helping to control, reduce, or reverse the disease.

05: The aim is for the body to replenish with its own healthy B cells.

Therapy

Chimeric antigen receptor (CAR) T-cell therapies

Format

Autologous (KYV-101) and allogeneic
(KYV-201)

Disease Target

B cell-driven autoimmune diseases

Clinical Trials

Lupus nephritis Systemic sclerosis Myasthenia gravis Multiple sclerosis

Clinical trials

Participation in clinical trials is the best way to access our investigational product. Kyverna may consider requests for expanded access when alternative therapy options have been exhausted.